Daxor Corporation to Present at the H.C. Wainwright & Company Global Investment Conference
May 12, 2022 08:00 ET
|
Daxor Corporation
NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that President and CEO Michael Feldschuh will...
New Data Validates Blood Volume Analysis Guided-Care, Improves Survival in Patients with Advanced Heart Failure Supported with Left Ventricular Assist Device
May 02, 2022 08:00 ET
|
Daxor Corporation
Study Presented at the International Society for Heart and Lung Transplant 42nd Annual Meeting and Scientific Sessions 2022 Oak Ridge, TN, May 02, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation...
New Study from Duke Heart Demonstrates the Unique Accuracy and Utility of Daxor’s Blood Volume Diagnostic (BVA-100®) for Improving Worsening Heart Failure
April 06, 2022 08:00 ET
|
Daxor Corporation
Study Presented at the 71st Annual American College of Cardiology Meeting Oak Ridge, TN, April 06, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume...
Daxor Corporation to Participate in the Maxim Group 2022 Virtual Growth Conference
March 23, 2022 08:00 ET
|
Daxor Corporation
Oak Ridge, TN, March 23, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces that President and CEO Michael Feldschuh will...
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
March 01, 2022 09:00 ET
|
Daxor Corporation
Oak Ridge, TN, March 01, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today issued a corporate update in a Letter to...
Daxor Corporation Announces $1.35 Per Share NAV Increase and Files Annual Report for Fiscal 2021
March 01, 2022 08:00 ET
|
Daxor Corporation
Revenues of Operating Division Increase by 70.6% Oak Ridge, TN, March 01, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, filed...
Study Demonstrates Importance and Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Assessment of Heart Failure
February 17, 2022 08:00 ET
|
Daxor Corporation
Daxor’s BVA-100® Shown to Provide Unique and Actionable Data for Addressing Heart Failure Oak Ridge, TN, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in...
Daxor Corporation Commences Trading on The NASDAQ Capital Market
February 02, 2022 08:00 ET
|
Daxor Corporation
Management to Ring the Nasdaq Stock Market Opening Bell on February 4, 2022 Oak Ridge, TN, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume...
Caleb DesRosiers, JD, MPA Appointed to Daxor Corporation Board of Directors
January 21, 2022 08:00 ET
|
Daxor Corporation
Oak Ridge, TN, Jan. 21, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, announced today that it has appointed Caleb DesRosiers, JD,...
Daxor Corporation to Commence Trading on The Nasdaq Capital Market On February 2, 2022
January 20, 2022 16:05 ET
|
Daxor Corporation
Oak Ridge, TN, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that it will commence trading on The Nasdaq...